ATRIUM THERAPEUTICS INC share price logo

ATRIUM THERAPEUTICS INC Share Price

NASDAQ: RNA

Small Cap

$14.56

-0.24

(-1.62%)

as on

ATRIUM THERAPEUTICS INC Stock Performance

as on March 13, 2026 at 1:06 am IST

  • Day's Low

    Day's High

    $14.45
    $14.73
    downward going graph

    0.76%

    Downside

    1.17%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $13.06
    $73.06
    downward going graph

    10.30%

    Downside

    401.79%

    Upside

    downward going graph

ATRIUM THERAPEUTICS INC share price movements today

Previous Close
$14.80
Open
$14.70
Volume
136.5K
Day's Low - High
$14.45 - $14.73
52 Week Low - High
$13.06 - $73.06

ATRIUM THERAPEUTICS INC Historical Returns

1 Month Return
-79.7 %
3 Month Return
-79.4 %
1 Year Return
-54.62 %
3 Year Return
-27.91 %
5 Year Return
0 %

ATRIUM THERAPEUTICS INC Stock Fundamentals & Key Indicators

Check ATRIUM THERAPEUTICS INC market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$227.6M

EPS (TTM)

-4.14

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-18.55

Industry PE ratio

7.871681415929204

PEG Ratio

0

EBITDA

-49.3M

Revenue (TTM)

18.6M

Profit Margin

-265.88%

Return On Equity TTM

-43.98%

ATRIUM THERAPEUTICS INC Stock Valuation

Track how ATRIUM THERAPEUTICS INC P/E has moved over time to understand its valuation trends.

ATRIUM THERAPEUTICS INC in the last 5 years

  • Overview

  • Trends

Lowest (-15.07x)

September 30, 2024

Today (-18.55x)

March 12, 2026

Industry (7.87x)

March 12, 2026

Highest (-2.31x)

December 31, 2023

LowHigh

Today’s Price to Earnings Ratio: -18.55x

ATRIUM THERAPEUTICS INC vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of ATRIUM THERAPEUTICS INC with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
ATRIUM THERAPEUTICS INC image
ATRIUM THERAPEUTICS INC
BUY$227.6MNA-18.55-265.88%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$42.8B125.34%138.968.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$126.8B129.73%32.5832.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$35.3BNA123.645.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$81.6B64.31%18.6231.41%

Stock Returns calculator for ATRIUM THERAPEUTICS INC Stock including INR - Dollar returns

The ATRIUM THERAPEUTICS INC stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

ATRIUM THERAPEUTICS INC investment value today

Current value as on today

₹50,385

Returns

₹49,615

(-49.61%)

Returns from ATRIUM THERAPEUTICS INC Stock

₹55,351 (-55.35%)

Dollar Returns*

₹5,737 (+5.74%)

Analyst Recommendation on ATRIUM THERAPEUTICS INC Stock

Based on 12 analysts

BUY

91.67%

Buy

8.33%

Hold

0.00%

Sell

Based on 12 analysts, 91.67% of analysts recommend a 'BUY' rating for ATRIUM THERAPEUTICS INC. Average target price of $25

ATRIUM THERAPEUTICS INC Share Price Target

Get share price movements and forecasts by analysts on ATRIUM THERAPEUTICS INC.

What analysts predicted

41.76%UPSIDE

Target Price

$25

Current Price

$14.56

Analyzed by

12 Analysts

Target

$25.00

ATRIUM THERAPEUTICS INC target price $25, a slight upside of 41.76% compared to current price of $14.56. According to 12 analysts rating.

ATRIUM THERAPEUTICS INC Stock’s Investor Sentiment and Interest

Search interest for ATRIUM THERAPEUTICS INC Stock has increased by 112% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:112% versus previous 30 day period

ATRIUM THERAPEUTICS INC Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
2
2
3
2
2
2
1
3
12
0
Gross Profit
-44
1
2
1
2
2
1
-134
12
0
Operating Income
-58
-66
-77
-82
-98
-120
-131
-171
-188
-254
EBITDA
-58
-66
-76
-81
-97
-120
-130
-170
-173
-231
Interest Expense
-
0
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
1
0
Income Before Tax
-52
-60
-68
-70
-80
-102
-115
-157
-174
-237
Income Tax Expense
-6
0
0
-
-
-
-
-
-
-
Net Income
-52
-60
-68
-70
-80
-102
-115
-157
-174
-237
Net Profit Margin
-1857.98%
-2756.18%
-1943.41%
-3461.76%
-3441.70%
-3439.52%
-7360.01%
-4089.29%
-1398.33%
-27569.88%

ATRIUM THERAPEUTICS INC Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
2
6
9
9
9
10
18
Gross Profit
-8
2
6
9
9
7
10
14
Operating Income
-10
-17
-44
-118
-178
-235
-378
-745
EBITDA
-10
-16
-43
-117
-177
-233
-376
-680
Interest Expense
0
7
0
0
5
-
-
-
Depreciation
0
0
0
0
1
1
2
0
Income Before Tax
-11
-24
-44
-118
-173
-212
-322
-684
Income Tax Expense
0
7
0
0
-4
1
-
-
Net Income
-11
-24
-43
-117
-169
-212
-322
-684
Net Profit Margin
-3148.81%
-1066.58%
-648.03%
-1258.52%
-1833.01%
-2219.87%
-2957.71%
-3650.39%

ATRIUM THERAPEUTICS INC Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-60
-68
-70
-80
-102
-115
-157
-174
-237
Operating Cash Flow
16
-70
-65
-65
-99
-124
-199
-156
-169
Investing Cash Flow
51
-32
-274
-482
-64
157
185
-587
207
Financing Cash Flow
31
389
446
342
13
1
3
850
-5
Change in Cash
99
286
106
-205
-150
34
-10
106
32

ATRIUM THERAPEUTICS INC Annual Cash Flow

All numbers in Millions USD

Dec 2013
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-
-11
-24
-44
-118
-173
-212
-322
-684
Operating Cash Flow
-
-9
2
-37
-94
-136
-119
-300
-650
Investing Cash Flow
-
0
0
-7
-82
-189
-130
-854
-38
Financing Cash Flow
88
5
89
272
176
346
93
1,192
850
Change in Cash
-
-4
91
227
-1
19
-155
37
162

Global Institutional Holdings in ATRIUM THERAPEUTICS INC

Funds
Holdings
Pentwater Capital Management LP
3.88%
venBio Select Advisor LLC
4.93%
JPMorgan Chase & Co
1.16%
Bank of America Corp
1.11%
Siren, L.L.C.
0.86%
See all

ATRIUM THERAPEUTICS INC News & Key Events

    Insights on ATRIUM THERAPEUTICS INC

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgNO EFFECT

      Against Peers

      img

      In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 32.2% return, outperforming this stock by 86.8%

    • imgNO EFFECT

      Against Peers

      img

      In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 75.4% return, outperforming this stock by 103.3%

    • imgNEGATIVE IMPACT

      Revenue Fall

      img

      Revenue is down for the last 2 quarters, 12.47M → 860.0K (in $), with an average decrease of 93.1% per quarter

    • imgNEGATIVE IMPACT

      Price Dip

      img

      In the last 1 month, RNA stock has moved down by -79.7%

    • imgNEGATIVE IMPACT

      Profit Down

      img

      Netprofit is down for the last 11 quarters, -47.02M → -237.10M (in $), with an average decrease of 18.0% per quarter

    About ATRIUM THERAPEUTICS INC

    avidity biosciences is pioneering a new class of precision medicines – antibody-sirna conjugates (asc™) – to deliver nucleic acid therapeutics against genetic drivers of disease. our ascs have drug-like properties similar to antibodies and antibody-drug conjugates. importantly, their unique sirna-based “payloads” permit selective targeting of disease-associated mrnas against virtually any target of interest. our leadership includes seasoned scientists and executives with deep expertise in the fields of antibody conjugation, chemistry, formulations, oligonucleotide therapeutics, drug delivery and cancer biology. our employees are high energy, creative people who are passionate about solving hard problems and bringing new drugs to patients. we strive to work with partners to discover best-in-class molecules with the goal of long-term, joint value creation. we have also attracted support from top-tier investors including f-prime capital, ecor1 capital, brace pharma and other sophisticated
    OrganisationATRIUM THERAPEUTICS INC
    Headquarters10578 Science Center Drive, San Diego, CA, United States, 92121
    IndustryHealth Technology
    CEOMs. Kathleen P. Gallagher
    E-voting on sharesClick here to vote

    Key Management of ATRIUM THERAPEUTICS INC

    Name

    Title

    Ms. Rocio Martin Hoyos

    Chief Strategy Officer

    Ms. Kathleen P. Gallagher

    President, CEO & Director

    Mr. Brendan Winslow

    Chief Financial Officer

    Dr. Husam Younis

    Chief Scientific Officer

    Ms. Stephanie Kenney

    Chief Corporate Affairs Officer

    Dr. Steven George Hughes M.B.A., M.D.

    Chief Medical Officer

    FAQs

    What is ATRIUM THERAPEUTICS INC share price today?

    ATRIUM THERAPEUTICS INC share price today is $14.56 as on at the close of the market. ATRIUM THERAPEUTICS INC share today touched a day high of $14.73 and a low of $14.45.

    What is the 52 week high and 52 week low for ATRIUM THERAPEUTICS INC share?

    ATRIUM THERAPEUTICS INC share touched a 52 week high of $73.06 on and a 52 week low of $13.06 on . ATRIUM THERAPEUTICS INC stock price today i.e. is closed at $14.56,which is 80.07% down from its 52 week high and 11.49% up from its 52 week low.

    What is ATRIUM THERAPEUTICS INC's market capitalisation today?

    ATRIUM THERAPEUTICS INC market capitalisation is $0.00T as on .

    How to invest in ATRIUM THERAPEUTICS INC Stock (RNA) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for ATRIUM THERAPEUTICS INC on INDmoney app. Click on Buy button. You can invest as low as $1.5 in ATRIUM THERAPEUTICS INC Shares that will get you 0.1030 shares as per ATRIUM THERAPEUTICS INC share price of $14.56 per share as on March 12, 2026 at 7:36 pm IST.

    What is the minimum amount required to buy ATRIUM THERAPEUTICS INC Stock (RNA) from India?

    Indian investors can start investing in ATRIUM THERAPEUTICS INC (RNA) shares with as little as ₹92.206 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹922.06 in ATRIUM THERAPEUTICS INC stock (as per the Rupee-Dollar exchange rate as on ). Based on ATRIUM THERAPEUTICS INC share’s latest price of $14.56 as on March 12, 2026 at 7:36 pm IST, you will get 0.6868 shares of ATRIUM THERAPEUTICS INC. Learn more about fractional shares .